Autoantibodies Against Methylglyoxal-Modified Apolipoprotein B100 and ApoB100 Peptide Are Associated With Less Coronary Artery Atherosclerosis and Retinopathy in Long-Term Type 1 Diabetes
Research Design and Methods: IgM and IgG against MGO-apoB100 and MGO-p5 were measured by ELISA in plasma from 103 type 1 diabetessubjects and 63 controls (Dialong study) and in a replication cohort of 27 type 1 diabetes subjects (Oslo study). Coronary atherosclerosis was assessed by computer tomography coronary angiography or intravascular ultrasound. Retinopathy was classified by retinal photos.
Results: MGO-ApoB100 IgM and MGO-p5 IgM levels were higher in diabetes subjects with no coronary artery stenosis compared to subjects with significant stenosis (median (IQR): 96.2 AU (71-126.8) vs. 54 AU (36.1-85.4), p=0.003 for MGO-ApoB100, and 77.4 AU (58-106) vs 36.9 AU (28.9-57.4), p=0.005 for MGO-p5). MGO-ApoB100 IgM and MGO-p5 IgM were associated with less severe coronary stenosis after adjusting for confounders (odds ratio (95% CI): 0.2 (0.05-0.6), p=0.01 and 0.22 (0.06-0.75), p=0.02. The inverse association of MGO-p5 IgM and coronary stenosis was confirmed in the replication cohort. Subjects with proliferative retinopathy had significantly lower MGO-ApoB100 IgM and MGO-p5 IgM than those with background retinopathy.
Conclusions: Autoantibodies against AGE-modified apoB100 are inversely associated with coronary atherosclerosis and proliferative retinopathy, suggesting vascular protective effects of these autoantibodies in type 1 diabetes.
